Trade Amphastar Pharmaceuticals Inc - AMPH CFD

Amphastar P Company profile

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API, products. It manufactures and sells over 20 products. It operates through two segments: finished pharmaceutical products and API products. It marketed products include Primatene Mist, Enoxaparin, Glucagon for Injection Emergency Kit, Naloxone and Other finished pharmaceutical products. Primatene Mist, an over-the-counter epinephrine inhalation product, is indicated for the temporary relief of mild symptoms of intermittent asthma. Enoxaparin is an injectable form of low molecular weight heparin that is used as an anticoagulant, which is indicated for multiple indications, including the prevention and treatment of deep vein thrombosis. Glucagon for injection is a difficult to manufacture injectable product.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Amphastar Pharmaceuticals Inc revenues increased 25% to $437.8M. Net income increased from $1.4M to $62.1M. Revenues reflect Pharmaceutical segment increase of 27% to $419.6M, United States segment increase of 26% to $419.9M, China segment increase of 90% to $6M. Net income benefited from Research and development decrease of 13% to $48.2M (expense).